Fresenius Kabi Recalls two Lots of Fluorouracil Injection
Fresenius Kabi recalls chemotherapy drug because of possible glass particulate within the drug vials.
Fresenius Kabi USA announced on July 1, 2019 that it was recalling two lots of Fluorouracil Injection USP 5 g/ 100 mL, 100 mL fill in 100mL vials to the user level because of possible glass particulate within the drug vials. The company reported that glass particulate was found in five vials during a quality inspection of one lot of the drug product. A second lot produced in the same filling campaign was included in the recall as a precautionary measure.
Using drug products containing glass particulate could cause a sequelae of thromboembolism, such as pulmonary emboli, phlebitis, granulomas, or fibrosis, according to the company.
The recalled lots, numbers 6120341 and 6120420 were distributed between Dec. 6, 2018 and Feb. 20, 2019 and have expiration dates of April 2020.
Fresenius Kabi is asking customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product.
Fluorouracil Injection is an intravenous chemotherapy drug that treats an array of cancers.
The recall notice was announced by Fresenius Kabi on the FDA website.
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
